Skip to main content

Advertisement

SpringerLink
Log in

Comprehensive lung injury pathology induced by mTOR inhibitors

  • Educational Series
  • Molecular Targets in Oncology
  • Published:
Clinical and Translational Oncology Aims and scope Submit manuscript

Abstract

Interstitial lung disease is a rare side effect of temsirolimus treatment in renal cancer patients. Pulmonary fibrosis is characterised by the accumulation of extracellular matrix collagen, fibroblast proliferation and migration, and loss of alveolar gas exchange units. Previous studies of pulmonary fibrosis have mainly focused on the fibro-proliferative process in the lungs. However, the molecular mechanism by which sirolimus promotes lung fibrosis remains elusive. Here, we propose an overall cascade hypothesis of interstitial lung diseases that represents a common, partly underlying synergism among them as well as the lung pathogenesis side effects of mammalian target of rapamycin inhibitors.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Abraham RT (2004) PI3-kinase related kinases: “big” players in stress-induced signalling pathways. DNA Repair (Amst) 3:883–887

    Article  CAS  Google Scholar 

  2. Chen J, Zheng XF, Brown EJ, Schreiber SL (1995) Identification of an 11-kDa FKBP12-rapamycin-binding domain within the 289-kDa FKBP12-rapamycin-associated protein and characterization of a critical serine residue. Proc Natl Acad Sci USA 92:4947–4951

    Article  PubMed  CAS  Google Scholar 

  3. Jacinto E, Loewith R, Schmidt A et al (2004) Mammalian TOR complex 2 controls the actin cytoskeleton and is rapamycin insensitive. Nat Cell Biol 6:1122–1128

    Article  PubMed  CAS  Google Scholar 

  4. Sarbassov DD, Ali SM, Kim DH et al (2004) Rictor, a novel binding partner of mTOR, defines a rapamycin-insensitive and raptor-independent pathway that regulates the cytoskeleton. Curr Biol 14:1296–1302

    Article  PubMed  CAS  Google Scholar 

  5. Chan S (2004) Targeting the mammalian target of rapamycin (mTOR): a new approach to treating cancer. Br J Cancer 91:1420–1424

    Article  PubMed  CAS  Google Scholar 

  6. Atkins MB, Hidalgo M, Stadler WM et al (2004) Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma. J Clin Oncol 22:909–918

    Article  PubMed  CAS  Google Scholar 

  7. Duran I, Siu LL, Oza AM et al (2006) Characterisation of the lung toxicity of the cell cycle inhibitor temsirolimus. Eur J Cancer 42:1875–1880

    Article  PubMed  CAS  Google Scholar 

  8. Morelon E, Stern M, Kreis H (2000) Interstitial pneumonitis associated with sirolimus therapy in renal-transplant recipients. N Engl J Med 343:225–226

    Article  PubMed  CAS  Google Scholar 

  9. Morelon E, Manzer-Bruneel MF, Peraldi MN, Kreis H (2001) Sirolimus; a new promising immunosuppressive drug. Towards a rationale for its use in renal transplantation. Nephrol Dial Transplant 16:18–20

    Article  PubMed  CAS  Google Scholar 

  10. Pham PT, Pham PC, Danovitch GM et al (2004) Sirolimus-associated pulmonary toxicity. Transplantation 77:1215–1220

    Article  PubMed  CAS  Google Scholar 

  11. Singer SJ, Tiernan R, Sullivan EJ (2000) Interstitial pneumonitis associated with sirolimus therapy in renal-transplant recipients. N Engl J Med 343:1815–1816

    Article  PubMed  CAS  Google Scholar 

  12. Mahalati K (2000) Bronchiolitis obliterans and organizing pneumonia in renal transplant recipients. Transplantation 69:1581

    Google Scholar 

  13. Vignot S, Faivre S, Aguirre D, Raymond E (2005) mTOR-targeted therapy of cancer with rapamycin derivatives. Ann Oncol 16:525–537

    Article  PubMed  CAS  Google Scholar 

  14. Chan S, Scheulen ME, Johnston S et al (2005) Phase II study of temsirolimus (CCI-779), a novel inhibitor of mTOR, in heavily pretreated patients with locally advanced or metastatic breast cancer. J Clin Oncol 23:5314–5322

    Article  PubMed  CAS  Google Scholar 

  15. Galanis E, Buckner JC, Maurer MJ et al; North Central Cancer Treatment Group (2005) Phase II trial of emsirolimus (CCI-779) in recurrent glioblastoma multiforme: a North Central Cancer Treatment Group Study. J Clin Oncol 23:5294–5304

    Article  PubMed  CAS  Google Scholar 

  16. Witzig TE, Geyer SM, Ghobrial I et al (2005) Phase II trial of single-agent Temsirolimus (CCI-779) for relapse mantle cell lymphoma. J Clin Oncol 23:5347–5356

    Article  PubMed  CAS  Google Scholar 

  17. Israel-Biet D, Labrune S, Huchon GJ (1991) Drug-induced lung disease: review, 1990. Eur Respir J 4:465–478

    PubMed  CAS  Google Scholar 

  18. Kilburn KH (1980) Pulmonary disease induced by drugs. In: Fishman AP (ed.) Pulmonary disease and disorders. McGraw-Hill, New York, pp 707–724

    Google Scholar 

  19. Rosenow EC, Myers JL, Swensen SJ, Pisani RJ (1992) Drug-induced pulmonary disease: an update. Chest 102:239–250

    Article  PubMed  Google Scholar 

  20. Vahid B, Marik PE (2008) Pulmonary complications of novel antineoplastic agents for solid tumors. Chest 133:528–538

    Article  PubMed  CAS  Google Scholar 

  21. Weis RB, Muggia FM (1980) Cytotoxic druginduced pulmonary disease: update. Am J Med 68:259–266

    Article  Google Scholar 

  22. Whimster WF, de Poitiers W (1982) The lung. In: Riddell RH (ed.) Pathology of drug-induced and toxic diseases. Churchill Livingstone, New York, pp 167–200

    Google Scholar 

  23. Katzebstein ALA (1985) Pathogenesis of “fibrosis” in interstitial pneumonia: an electron microscopic study. Hum Pathol 16:1015–1024

    Article  Google Scholar 

  24. Crystal RG, Bitterman PB, Rennard SI et al (1984) Interstitial lung disease of unknown cause. Disorders characterized by chronic inflammation of the lower respiratory tract. N Engl J Med 310:154–166

    PubMed  CAS  Google Scholar 

  25. Rennard S, Bitterman P, Crystal R (1983) Response of the lower respiratory tract to injury. Mechanisms of repair of the parenchymal cells of the alveolar wall. Chest 84:735–739

    Article  PubMed  CAS  Google Scholar 

  26. Liebow A (1975) Definition and classification of interstitial pneumonia in human pathology. Prog Respir Res 8:1–33

    Google Scholar 

  27. Spencer H (1975) Pathogenesis of interstitial fibrosis of the lung. Prog Respir Res 8:34–44

    Google Scholar 

  28. Hussain SP, Hofseth LJ, Haris CC (2003) Radical causes of cancer. Nat Rev Cancer 3:276–285

    Article  PubMed  CAS  Google Scholar 

  29. Ohshima H, Tatemichi M, Sawa T (2003) Chemical basis of inflammation-induced carcinogenesis. Arch Biochem Biophys 417:3–11

    Article  PubMed  CAS  Google Scholar 

  30. Chen LF, Williams SA, Mu Y et al (2005) NFkappaB RelA phosphorylation regulates RelA acetylation. Mol Cell Biol 25:7966–7975

    Article  PubMed  CAS  Google Scholar 

  31. Kiernan R (2003) Post-activation turn-off NFkappa B-dependent transcription is regulated by acetylation of p65. J Biol Chem 278:2758–2766

    Article  PubMed  CAS  Google Scholar 

  32. Barnes PJ, Karin M (1997) Nuclear factor-kappaB: a pivotal transcription factor in chronic inflammatory diseases. N Engl J Med 336:1066–1071

    Article  PubMed  CAS  Google Scholar 

  33. Ghosh S, Karin M (2002) Missing pieces in the NF-kB puzzle. Cell 109:S81–96

    Article  PubMed  CAS  Google Scholar 

  34. Hoffmann A, Levchenko A, Scott ML, Baltimore D (2002). The IkappaB-NF-kappaB signalling module: temporal control and selective gene activation. Science 298:1241–1245

    Article  PubMed  CAS  Google Scholar 

  35. Hoffmann A, Leung TH, Baltimore D (2003) Genetic analysis of NF-kappaB/rel transcription factors defines functional specificities. EMBO J 22:5530–5539

    Article  PubMed  CAS  Google Scholar 

  36. Jacobs MN, Harrison SD (1998) Structure of an I-kBa/NF-kB complex. Cell 95:749–758

    Article  PubMed  CAS  Google Scholar 

  37. Chen LW, Egan L, Li ZW et al (2003) The two faces of IKK and NF-kappaB inhibition: prevention of systemic inflammation but increased local injury following intestinal ischemia-reperfusion. Nat Med 9:575–581

    Article  PubMed  CAS  Google Scholar 

  38. Li Q, Verma IM (2002) NF-kB regulation in the immune system. Nat Rev Immunol 2:725–734

    Article  PubMed  CAS  Google Scholar 

  39. Maeda S, Chang L, Li ZW et al (2003) IKKbeta is required for prevention of apoptosis mediated by cell-bound but not by circulating TNF alpha. Immunity 19:725–737

    Article  PubMed  CAS  Google Scholar 

  40. Moore KJ, Rosen ED, Fitzgerald ML et al (2001) The role of PPAR-gamma in macrophage differentiation and cholesterol uptake. Nat Med 7:41–47

    Article  PubMed  CAS  Google Scholar 

  41. Petersen KF, Dufour S, Befroy D et al (2004) Impaired mitochondrial activity in the insulinresistant offspring of patients with type 2 diabetes. N Engl J Med 350:664–671

    Article  PubMed  CAS  Google Scholar 

  42. Castranova VD, Porter L, Millecchia JY et al (2002) Effect of inhaled crystalline silica in rat model: time course of pulmonary reactions. Mol Cell Biochem 234–235:177–184

    Article  PubMed  Google Scholar 

  43. Shukla A, Ramos-Nino M, Mossman B (2003) Cell signalling and transcription factor activation by asbestos in lung injury and disease. Int J Biochem Cell Biol 35:1198–1209

    Article  PubMed  CAS  Google Scholar 

  44. Arslan SO, Zerin M, Vural H, Coskun A (2002) The effect of melatonin on bleomycin-induced pulmonary fibrosis in rats. J Pineal Res 32:21–25

    Article  PubMed  CAS  Google Scholar 

  45. Chen J, Stubbe J (2004) Bleomycins: a new methods will allow reinvestigation of old issues. Curr Opin Cell Biol 8:175–181

    CAS  Google Scholar 

  46. Hubbard AK, Timblin CR, Shukla A et al (2002) Activation of NF-kB-dependent gene expression by silica in lungs of luciferase reporter mice. Am J Physiol Lung Cell Mol Physiol 282:L968–975

    PubMed  CAS  Google Scholar 

  47. Benjamin RC, Gill DM (1980) Poly(ADP-ribose) synthesis in vitro programmed by damaged DNA. A comparison of DNA molecules containing different types of strands breaks. J Biol Chem 255:10502–10508

    PubMed  CAS  Google Scholar 

  48. Cosi C, Marien M (1999) Implication of poly(ADP-ribose)polymerase (PARP) in neurodegeneration and brain energy metabolism. Decreases in mouse brain NAD+ and ATP caused by MPTP are prevented by the PARP inhibitor benzamide. Ann NY Acad Sci 890:227–239

    Article  PubMed  CAS  Google Scholar 

  49. Virag L (2005) Poly(ADP-ribosyl)ation in asthma and other lung diseases. Pharmacol Res 52:83–92

    Article  PubMed  CAS  Google Scholar 

  50. Fattman CL, Chang LY, Termin TA et al (2003) Enhanced bleomycin-induced pulmonary damage in mice lacking extracellular superoxide dismutase. Free Radic Biol Med 35:763–771

    Article  PubMed  CAS  Google Scholar 

  51. Griffith OW, Stuehr DJ (1995) Nitric oxide synthase: properties and catalytic mechanism. Annu Rev Physiol 57:707–736

    Article  PubMed  CAS  Google Scholar 

  52. Halliwell B (1997) What nitrates tyrosine? Is nitrotyrosine specific as a biomarker of peroxynitrite formation in vivo? FEBS Lett 411:157–160

    Article  PubMed  CAS  Google Scholar 

  53. Adamsson IY, Bowden DH (1974) The pathogenesis of bleomycin-induced pulmonary fibrosis in mice. Am J Pathol 77:185–197

    Google Scholar 

  54. Fasske E, Morgenroth K (1983) Experimental bleomycin lung in mice. A contribution to the pathogenesis of pulmonary fibrosis. Lung 161:133–146

    Article  PubMed  CAS  Google Scholar 

  55. Chakrabarti S, Makrigiorgos GM, O’Brien K et al (1996) Measurement of hydroxyl radicals catalyzed in the immediate vicinity of DNA by metal-bleomycin complexes. Free Radic Biol Med 20:777–783

    Article  PubMed  CAS  Google Scholar 

  56. Conley NS, Yarbro JW, Ferrari HA, Zeidler RB (1986) Bleomycin increases superoxide anion generation by pig peripheral alveolar macrophages. Mol Pharmacol 30:48–52

    PubMed  CAS  Google Scholar 

  57. Tarnell EW, Oliver BL, Johnsson GM et al (1992) Superoxide anion production by rat neutrophils at various stages of belomycin-induced lung injury. Lung 170:41–50

    Article  PubMed  CAS  Google Scholar 

  58. Moncada S, Palmer RM, Higgs EA (1989) Biosynthesis of nitric oxide from L-arginine. A pathway for the regulation of cell function and communication. Biochem Pharmacol 38:1709–1715

    Article  PubMed  CAS  Google Scholar 

  59. Forstermann U, Gath I, Schwarz P et al (1995) Isoforms of nitric oxide synthase. Properties, cellular distribution and expressional control. Biochem Pharmacol 50:1321–1332

    CAS  Google Scholar 

  60. Cuzzocrea S, Zingarelli B, Hake P et al (1998) Antiinflammatory effects of mercaptoethylguanidine, a combined inhibitor of nitric oxide synthase and peroxynitrite scavenger, in carrageenan-induced models of inflammation. Free Radic Biol Med 24:450–459

    Article  PubMed  CAS  Google Scholar 

  61. Wei XD, Charles IG, Smith A et al (1995) Altered immune responses in mice lacking inducible nitric oxide synthase. Nature 375:408–411

    Article  PubMed  CAS  Google Scholar 

  62. Gansauge S, Gansauge F, Nussler AK et al (1997) Exogenous, but not endogenous, nitric oxide increases proliferation rates in senescent human fibroblasts. FEBS Lett 410:160–164

    Article  PubMed  CAS  Google Scholar 

  63. Romanska HM, Polak JM, Colemena RA et al (2002) iNOS gene upregulation is associated with the early proliferative response of human lung fibroblasts to cytokine stimulation. J Pathol 197:372–379

    Article  PubMed  CAS  Google Scholar 

  64. Saleh D, Barnes PJ, Giaid A (1997) Increased production of the potent oxidant peroxynitrite in the lungs of patients with idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 155:1763–1769

    PubMed  CAS  Google Scholar 

  65. Ask K, Maretin GE, Kolb M, Gauldie J (2006) Targeting genes for treatment in idiopathic pulmonary fibrosis: challenges and opportunities, promises and pitfalls. Proc Am Thorac Soc 3:389–393

    Article  PubMed  CAS  Google Scholar 

  66. Sporn MB, Roberts AB, Wakefield LM, de Crombrugghe B (1987). Some recent advances in the chemistry and biology of transforming growth factor-β. J Cell Biol 105:1039–1045

    Article  PubMed  CAS  Google Scholar 

  67. Fine A, Goldstein RH (1987) The effect of transforming growth factor-β on cell proliferation and collagen formation by lung fibroblasts. J Biol Chem 262:3897–3902

    PubMed  CAS  Google Scholar 

  68. Moses HL, Branum EL, Proper JA, Robinson RA (1981) Transforming growth factor production by chemically transformed cells. Cancer Res 41:2842–2848

    PubMed  CAS  Google Scholar 

  69. Roberts AB, Lamb LC, Newton DL et al (1980) Transforming growth factors: isolation of polypeptides from virally and chemical transformed cells by acid/ethanol extraction. Proc Natl Acad Sci USA 77:3494–3498

    Article  PubMed  CAS  Google Scholar 

  70. Gotzman J, Mikula M, Eger A et al (2004) Molecular aspects of epithelial cell plasticity: implications for local tumor invasion and metastasis. Mutat Res 566:9–20

    Article  CAS  Google Scholar 

  71. Tosh D, Slack JM (2002) How cells changes their phenotype. Nat Rev Mol Cell Biol 3:187–194

    Article  PubMed  CAS  Google Scholar 

  72. Roberts AB, Sporn MB (1993) Physiological actions and clinical applications of transforming growth factor-β (TFG-β). Growth Factors 8:1–9

    Article  PubMed  CAS  Google Scholar 

  73. Janda E, Lehmann K, Killisch I et al (2002) Ras and TGF(beta) cooperatively regulate epithelial cell plasticity and metastasis: dissection of Ras signalling pathways. J Cell Biol 156:299–313

    Article  PubMed  CAS  Google Scholar 

  74. Peinado H, Quintanilla M, Cano A (2003) Transforming growth factor beta-1 induces snail transcription factor in epithelial cell lines: mechanisms for epithelial mesenchymal transition. J Biol Chem 278:21113–21123

    Article  PubMed  CAS  Google Scholar 

  75. Hoyt DG, Lazo JS (1988) Alterations in pulmonary mRNA encoding procollagens, fibronectin and transforming growth factor-β precede bleomycin-induced pulmonary fibrosis in mice. J Pharmacol Exp Ther 246:765–771

    PubMed  CAS  Google Scholar 

  76. Barral-Neto M, Barral A, Brownel CE et al (1992) Transforming growth factor β in leishmanial infection: a parasite escape mechanism. Science 257:545–548

    Article  Google Scholar 

  77. Zhang K, Rekhter MD, Gordon D, Phan SH (1994) Localization of myofibroblasts in the lung, and their role in collagen gene expression in a model of pulmonary fibrosis. Am J Pathol 145:114–125

    PubMed  CAS  Google Scholar 

  78. Li MO, Wan YY, Sanjabi S et al (2006) Transforming growth factor-beta regulation of immune responses. Annu Rev Immunol 24:99–146

    Article  PubMed  CAS  Google Scholar 

  79. Rubtsov YP, Rudensky AY (2007) TGFbeta signalling in control of T-cell-mediated self-reactivity. Nat Rev Immunol 7:443–453

    Article  PubMed  CAS  Google Scholar 

  80. Khalil N, Corne S, Whitman C, Yacyshyn H (1996) Plasmin regulates the activation of cell-associated latent TGF-β secreted by rat alveolar macrophages after in vivo bleomycin injury. Am J Resp Cell Mol Biol 15:252–259

    CAS  Google Scholar 

  81. Broekelmann TJ, Limper AH, Colby TV, McDonald JA (1991) Transforming growth factor β1 is present at sites of extracellular matrix gene expression in human pulmonary fibrosis. Proc Natl Acad Sci USA 88:6642–664

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Oncology Research Lab, INIBIC, A Coruña, Spain

    Guadalupe Aparicio & Vanessa Medina

  2. INIBIC, A Coruña University Hospital, A Coruña, Spain

    Moisés B. Calvo & Angélica Figueroa

  3. Medical Oncology Service, A Coruña University Hospital, C/ As Xubias, s/n, ES-15006, A Coruña, Spain

    Ovidio Fernández & Luis M. Antón Aparicio

  4. Medical Oncology Service, Asturias Central Hospital, Oviedo, Spain

    Paula Jiménez

  5. Pharmacy Service, A Coruña University Hospital, A Coruña, Spain

    Martina Lema

  6. Medicine Department, University of A Coruña, A Coruña, Spain

    Luis M. Antón Aparicio

Authors
  1. Guadalupe Aparicio
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Moisés B. Calvo
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Vanessa Medina
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Ovidio Fernández
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Paula Jiménez
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Martina Lema
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Angélica Figueroa
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Luis M. Antón Aparicio
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Luis M. Antón Aparicio.

Additional information

Supported by an unrestricted educational grant from Pfizer

Rights and permissions

Reprints and permissions

About this article

Cite this article

Aparicio, G., Calvo, M.B., Medina, V. et al. Comprehensive lung injury pathology induced by mTOR inhibitors. Clin Transl Oncol 11, 499–510 (2009). https://doi.org/10.1007/s12094-009-0394-y

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12094-009-0394-y

Keywords

Search

Navigation